Skip to Content
Merck
CN
  • Evaluation of reduction-mediated labelling of antibodies with technetium-99m.

Evaluation of reduction-mediated labelling of antibodies with technetium-99m.

International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology (1992-08-01)
Z M Zhang, J R Ballinger, K Sheldon, I Boxen
ABSTRACT

Monoclonal antibodies can be labelled with technetium-99m by prereduction of the antibody with 2-mercaptoethanol, then reduction of pertechnetate with an aliquot of a stannous kit, resulting in greater than 97% labelling without the need for further purification. The present work shows that equally high labelling can be obtained with a variety of weak ligands and that the optimum quantity of stannous chloride is 2-4 micrograms. Although the label was stable to challenge with excess DTPA, cysteine was able to remove a portion of the label. We have also shown that this technique works with the IgG2a isotype in addition to the previously reported IgG1 isotype. This approach is simple, convenient and reproducible, and warrants further clinical evaluation.